Abstract 3430: How important is the “post TMZ-treatment recovery” of GBM neoplastic cells

• Published in: Cancer research (Chicago, Ill.) Ill.), 2013-04, Vol.73 (8_Supplement), p.3430-3430
• Main Authors: Sarkar Roy, Neeta, Biswas, Nidhan, Chandra, Vikas, Das, Tapojyoti, Chatterjee, Ankita, Bhattacharya, Rabindra Narayan, Tripathy, Laxminarayan, Basu, Sunandan, Maitra, Arindam, Basu, Pryiadarshi, Basu, Analabha, Dhara, Surajit
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2013-3430

Glioblastoma multiforme (GBM) is the most prevalent central nervous system malignancy portending dismal prognosis. The median overall survival (OS) is 14.6 months with currently available standard care of surgery, radiotherapy and Temozolomide (TMZ) chemotherapy. TMZ, which is the best chemotherapeutic drug till date for this malignancy, gives a median OS advantage of only 2.5 months over surgery and radiotherapy alone. It is not clear how the benefit of TMZ is severely limited in a large majority of patients. To understand this we investigated genome wide sequence alterations of GBM neoplastic cells in response to TMZ. We present here two cases of GBM, A49910 and M45481, where the first one (A49910) showed response and the second one (M45481) showed no response to standard treatment in clinic. We isolated their primary tumor cells at the time of surgery and cultured them in vitro as neurospheres. When we exposed these two patient-derived neurospheres to clinically relevant dose of TMZ in vitro differential responses were observed among the two neurospheres which mirrored the clinical outcomes of the two patients respectively. Initially, at the end of 5 days of TMZ treatment, both A49910 and M45481 neurospheres showed 50% and 65% reduction in viable cell numbers respectively but after a 23 days of gap (“post TMZ-treatment recovery” from the 5 days long drug treatment), at 28th day of the treatment cycle, the total number of viable cells was 5% in TMZ-treated A49910 with a stark contrast of 60% in the TMZ-treated M45481 as compared to their respective DMSO-treated controls. Their growth curves, as measured by MTT assays, showed the exact reflection of this pattern, i.e., after 5 days of treatment both TMZ-treated A49910 and TMZ-treated M45481 showed equally retarded growth compared to their DMSO-treated controls, and at 28th day, only the TMZ-treated A49910 but not the TMZ-treated M45481 cells showed growth retardation. Moreover, almost every single cell of TMZ-treated A49910 appeared bigger and stained intensely with SA-βgal confirming drug induced senescence at 28th day whereas this phenotype was completely absent in TMZ-treated M45481, where no apparent sign of senescence was observed. However, apoptosis was two-fold higher in M45481 than in A49910 after 5 days of TMZ treatment. Whether this “drug induced cellular senescence (DICS)” phenotype is more beneficial to the patients claims further investigation with a larger cohort of GBM patients. For the pro